Terminated PHASE3 INTERVENTIONAL 2-arm NCT03227562

Is Initial Response to Low Dose Risperidone Predictive for Outcome in Anxiety?

Evaluation of Predictability of the Initial Response to a Low Dose of Risperidone on the Middle Term Efficiency in Anxious Subjects

Sponsor: Marion Trousselard

Conditions Anxiety State

Interventions RisperiDONE 0.5 MG

Updated 9 times since 2017 Last updated: Aug 2, 2022 Started: Sep 1, 2017 Primary completion: Sep 1, 2021 Completion: Dec 1, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

not enough patient

Other Anxiety State trials with similar outcome

NCT06420232 · Phase NA · Dec 2024

Browse all Anxiety State trials

This PHASE3 trial investigates Anxiety State and is currently terminated or withdrawn. Marion Trousselard leads this study, which shows 9 recorded versions since 2017 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Sep 2022 — Jul 2024 [monthly]

Terminated PHASE3

Status: Recruiting → Terminated
Sep 2021 — Sep 2022 [monthly]

Recruiting PHASE3
Jan 2021 — Sep 2021 [monthly]

Recruiting PHASE3

▶ Show 4 earlier versions

Mar 2019 — Jan 2021 [monthly]

Recruiting PHASE3
Jun 2018 — Mar 2019 [monthly]

Recruiting PHASE3
Mar 2018 — Jun 2018 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Aug 2017 — Mar 2018 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Marion Trousselard

Data source: Institut de Recherche Biomedicale des Armees

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Brétigny-sur-Orge, France